Healthy, Major Depressive Disorder, Major Depressive Disorder Remission
Conditions
Keywords
Theta-burst stimulation, Concurrent TBS/fNIRS, Verbal fluency task
Brief summary
The current study is a pilot for the GRF project entitled Predicting illness trajectories in fully remitted major depression using concurrent TBS/fNIRS. The project aims to determine whether immediate prefrontal excitability modulated by intermittent theta-burst stimulation (iTBS) is altered in remitted major depressive disorder (rMDD) and therefore classifies as a potential trait marker to predict the incidence of recurrence. In the present cross-sectional study, we will recruit four clusters of population, including patients diagnosed with rMDD, currently depressed patients with varying numbers of episodes, healthy subjects, and never-depressed healthy subjects with elevated risk for MDD (defined as having a first-degree relative with a history of depression), to investigate the relationship between the number of prior episodes, cognitive function, and TBS-induced instantaneous brain activity change in the presumed neuropathological prefrontal cortex (PFC).
Interventions
TBS comprises 3-pulse 50-Hz bursts, applied every 200 ms (at 5 Hz). iTBS consists of 2-second trains with an inter-train interval of 8 seconds. The investigators will repeat the trains (30 pulses; 10 bursts) 20 times to reach a total number of 600 pulses (3x10x20). Concurrent iTBS/fNIRS stimulation will be applied over the left DLPFC at an intensity of 90% resting motor threshold (RMT). This corresponds to \ 110% of the active motor threshold. Stimulation at 90% RMT will also ensure compliance, reduce sensory discomfort and minimize dropout rates. Still, scalp discomfort will be recorded directly after the stimulation. The stimulation site over the DLPFC will be determined using the international 10-20 system and correspond to the F3 label.
Sponsors
Study design
Eligibility
Inclusion criteria
* rMDD patients: (a) aged 18 to 65; (b) a clinical diagnosis of recurrent depressive disorder by an experienced psychiatrist but currently in full remission (ICD 11, 6A71.7) according to results of the Mini International Neuropsychiatric Interview (MINI) and the Patient Health Questionnaire (PHQ-9), with a score ≤ 4; (c) at least two previous MDEs within the last 10 years; (d) no or stable (≥4 weeks) psychopharmacological medication. Current MDD patients: (a) aged 18 to 65; (b) a clinical diagnosis of current unipolar depressive disorder by an experienced psychiatrist according to DSM-IV; (c) no or stable (≥4 weeks) psychopharmacological medication. HCs: (a) aged 18 to 65 and (b) healthiness based on history and psychiatric assessment. never-depressed HCs with elevated risk for MDD (HR-HCs): (a) aged 18 to 65, (b) healthiness based on history and psychiatric assessment and (c) with a family history of psychiatric illnesses.
Exclusion criteria
* rMDD patients: (a) severe internal diseases; (b) neurological disorders or a history of severe head injuries; (c) current psychiatric comorbidities, including addiction; (d) pregnancy; (e) common fNIRS and TMS
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Oxyhemoglobin (HbO) change compared to baseline | During and within 3 minutes post TBS-fNIRS measurement. | Primary imaging outcome measure: iTBS-induced HbO change in the bilater prefrontal cortex during and after stimulation. |
| Verbal fluency task induced-oxyhemoglobin (HbO) change compared to baseline | During the 60 seconds word-generation blocks. | Primary imaging outcome measure: cognitive task-induced HbO change in the bilateral prefrontal cortex. |
Countries
Hong Kong